Filtered By:
Infectious Disease: SARS
Therapy: Antiviral Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 427 results found since Jan 2013.
Antiviral therapy of coronavirus disease 2019 (COVID-19)
J Formos Med Assoc. 2023 Sep 2:S0929-6646(23)00342-X. doi: 10.1016/j.jfma.2023.08.029. Online ahead of print.ABSTRACTThe coronavirus disease 2019 (COVID-19) pandemic has reached a turning point. The non-pharmaceutical interventions for preventing COVID-19 are lifting. Vaccination uptake is increasing in general, but this strategy is continuously challenged by the rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Of note, the Omicron subvariants spread globally for at least one year, and the most recently developed subvariants show strong immune evasion to preexisting immunity, either from pre...
Source: J Formos Med Assoc - September 4, 2023 Category: General Medicine Authors: Pao-Yu Chen Jann-Tay Wang Shan-Chwen Chang Source Type: research
Evaluating Z-FA-FMK, a host cathepsin L protease inhibitor, as a potent and broad-spectrum antiviral therapy against SARS-CoV-2 and related coronaviruses
This study investigated the antiviral potential of Z-FA-FMK (FMK), a novel host cathepsin L protease inhibitor, against SARS-CoV-2 infection using both in vitro and in vivo models. In vitro assessments of FMK against a diverse set of SARS-CoV-2 strains, including the Wuhan-like strain and nine variants, demonstrated potent inhibition with EC50 values ranging from 0.55 to 2.41 μM, showcasing similar or superior efficacy compared to FDA-approved antivirals nirmatrelvir (NTV) and molnupiravir (MPV). In vivo experiments using orally administered FMK (25 mg/kg) in SARS-CoV-2-infected K18 hACE2 transgenic mice revealed improved...
Source: Antiviral Research - July 12, 2023 Category: Virology Authors: Ju Hwan Jeong Jang-Hoon Choi Beom Kyu Kim Seong Cheol Min Santosh Chokkakula Sol Oh Ji-Hyun Park Sang-Mu Shim Eung-Gook Kim Young Ki Choi Joo-Yeon Lee Yun Hee Baek Min-Suk Song Source Type: research
Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 infection
In this study, we evaluated the effect of potent selective cathepsin inhibitors as antiviral agents. We demonstrated that selective cathepsin B inhibitors, such as the antimicrobial agent nitroxoline and its derivatives, impair SARS-CoV-2 infection in vitro. Antiviral activity observed at early stage of virus entry was cell-type dependent and correlated well with the intracellular content and enzymatic function of cathepsins B or L. Furthermore, tested inhibitors were effective against the ancestral SARS-CoV-2 D614 as well as against the more recent BA.1_4 (Omicron). Taken together, our results highlight the important role...
Source: Cell Research - June 24, 2023 Category: Cytology Authors: Rafaela Milan Bonotto Ana Mitrovi ć Izidor Sosi č Pamela Martinez-Orellana Federica Dattola Stanislav Gobec Janko Kos Alessandro Marcello Source Type: research
In Silico Identification and Analysis of Potentially Bioactive Antiviral Phytochemicals against SARS-CoV-2: A Molecular Docking and Dynamics Simulation Approach
Biomed Res Int. 2023 May 11;2023:5469258. doi: 10.1155/2023/5469258. eCollection 2023.ABSTRACTSARS-CoV-2, a deadly coronavirus sparked COVID-19 pandemic around the globe. With an increased mutation rate, this infectious agent is highly transmissible inducing an escalated rate of infections and death everywhere. Hence, the discovery of a viable antiviral therapy option is urgent. Computational approaches have offered a revolutionary framework to identify novel antimicrobial treatment regimens and allow a quicker, cost-effective, and productive conversion into the health center by evaluating preliminary and safety investigat...
Source: Biomed Res - May 22, 2023 Category: Research Authors: Sajal Kumar Halder Ive Sultana Md Nazmussakib Shuvo Aparna Shil Mahbubul Kabir Himel Md Ashraful Hasan Mohammad Mahfuz Ali Khan Shawan Source Type: research
The SARS-CoV-2 papain-like protease suppresses type I interferon responses by deubiquitinating STING
Sci Signal. 2023 May 2;16(783):eadd0082. doi: 10.1126/scisignal.add0082. Epub 2023 May 2.ABSTRACTThe SARS-CoV-2 papain-like protease (PLpro), which has deubiquitinating activity, suppresses the type I interferon (IFN-I) antiviral response. We investigated the mechanism by which PLpro antagonizes cellular antiviral responses. In HEK392T cells, PLpro removed K63-linked polyubiquitin chains from Lys289 of the stimulator of interferon genes (STING). PLpro-mediated deubiquitination of STING disrupted the STING-IKKε-IRF3 complex that induces the production of IFN-β and IFN-stimulated cytokines and chemokines. In human airway c...
Source: Science Signaling - May 2, 2023 Category: Biomedical Science Authors: Dan Cao Lian Duan Bin Huang Yuxian Xiong Guoliang Zhang Hao Huang Source Type: research
